This week, seven biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

This week, La Jolla Pharmaceutical Company (LJPC) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

Incyte Corporation (INCY) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

This week, Lexicon Pharmaceuticals, Inc. (LXRX) pushes up from a C to a B rating. Lexicon Pharmaceuticals researches treatments for diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. For more information, get Portfolio Grader’s complete analysis of LXRX stock.

Ambit Biosciences Corp. (AMBI) shows solid improvement this week. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Progenics Pharmaceuticals, Inc. (PGNX) improves from a C to a B rating this week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Celladon Corporation (CLDN) is seeing ratings go up from a B last week to an A this week. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

This week, Tobira Therapeutics, Inc.’s (TBRA) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of TBRA stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.